ASTRAZENPharmaceuticals
AstraZeneca Pharma India Ltd — PE Ratio & Valuation Analysis
₹7931.00
-5.75%
Current P/E97.79xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E145.3x32.7% below avg
⚠️
207.8% Premium to Industry
ASTRAZEN P/E 97.79x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹46.30 | ₹9029 | 195x |
| 2024 | ₹64.60 | ₹7305 | 113.1x |
| 2023 | ₹39.70 | ₹5527 | 139.2x |
| 2022 | ₹24.60 | ₹3297 | 134x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding AstraZeneca Pharma India Ltd Valuation
AstraZeneca Pharma India Ltd (ASTRAZEN) currently trades at 97.79x earnings. The Pharmaceuticals sector average PE is 31.77x. ASTRAZEN commands a premium, reflecting high growth expectations. Historically, ASTRAZEN has traded at an average PE of 145.3x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
23.63%
Dividend Yield
0.35%
More on AstraZeneca Pharma India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.